Chronic myeloid leukaemia (CML) is a clonal disorder resulting in marked expansion in cells of the myeloid lineage, which invariably progresses in defined stages from the initial chronic phase to accelerated phase, and then blast crisis or acute leukaemia. The translocation resulting in the Philadelphia (Ph) chromosome leads to the production of BCR-ABL tyrosine kinase, and is present in virtually all patients. Although aIFN therapy successfully induces a haematological and cytogenetic response in CML, the associated side effects have been considerable. 1 Once progression to acute leukaemia has occurred from CML, standard chemotherapy results in only a limited response. 2 The signal transduction inhibitor, imatinib mesylate, (GLIVEC s ), selectively inhibits bcr-abl, c-kit and the platelet-derived growth factor (PDGF) receptor tyrosine kinases, competitively inhibiting ATP and preventing tyrosine phosphorylation of proteins involved in BCR-ABL signal transduction. 3 Imatinib mesylate has a significantly greater efficacy in comparison to IFN as a first-line treatment for CML. 1 It induces a complete haematological response rate in 490% of CP-CML and sustained haematological responses lasting at least 4 weeks in CML myeloid blast crisis in 31% of patients. 2 Imatinib mesylate has altered the clinical approach to other KIT-positive malignancies and, in particular, it is a promising treatment for gastrointestinal stromal tumours (GIST), which resist conventional chemotherapy. 4 The efficacy and safety of imatinib mesylate has previously been assessed. 3 Drug-related side effects are reportedly few, with grade III-IV nonhaematological toxicities occurring in o10% of patients. Reported nonhaematological adverse effects have included oedema, weight gain, nausea and vomiting, muscle cramps and diarrhoea. 5 In a total of 532 patients with chronic phase CML treated with 400 mg of imatinib mesylate daily, 32% were reported with a rash or related event. 5 Skin adverse events were also documented in a total of 23% of 260 patients with CML in myeloid blast crisis receiving imatinib mesylate orally at daily doses ranging from 400 to 600 mg. 2 At King's College Hospital, 11 of 41 consecutive CML patients (chronic phase n ¼ 6, accelerated phase n ¼ 5) developed a grade I-IV dermatosis, including one case with severe dose-limiting erythroderma. Six patients were male, five female. The median age range at the time of treatment was 63 years (range 48-66 years) ( Table 1) , duration of therapy prior to rash onset was 4 weeks (range 2-23 weeks), and starting dose was 400 mg (range 400-600 mg). The median evaluable white cell count (WCC) at the start of treatment was 10.7 Â 10 9 /l (4.2-76.0 Â 10 9 /l) and platelet count was 322 Â 10 9 /l (101-584 Â 10 9 /l) ( Table 1 ). All patients were initially treated with allopurinol, but all had tolerated allopurinol uneventfully in the past. Three of the 11 patients had unrelated pre-existing skin conditions. Morphologically, the adverse cutaneous effects were diverse. (Skin toxicity was graded 0-IV (defined as 0-none, I-faint erythema or dry desquamation, II-moderate to brisk erythema or a patchy moist desquamation mostly confined to skin folds/moderate oedema, III-confluent moist desquamation not confined to skin folds/pitting oedema, IV-skin necrosis/ulceration of full thickness dermis).) The eruptions ranged from a maculopapular to lichenoid reaction, eczema or psoriasis. Two patients exhibited striking skin reactions following imatinib mesylate treatment ( Figure 1 ). The dermatitis could be localised (eg severe periorbital reaction only), but was generally widespread. In one case (accelerated phase CML), severe dose-limiting erythroderma ( Figure 1 a-c) occurred predominantly on the face, spreading to the upper limbs and chest, associated with constitutional symptoms, including fever and dyspnoea. Skin biopsies in eight patients mainly showed a lymphocytic inflammatory infiltrate in a perivascular distribution and acanthosis ( Table 2 ). The features were consistent with a drug reaction, or incorporated lichenoid features (epidermal 'saw-tooth appearance', basal cell vacuolation together with dermal chronic inflammatory cell infiltrate and pigment incontinence. (n ¼ 3)). Eosinophils were predominantly absent. Representative skin biopsies are demonstrated in Figure 2 .
In five of the 11 patients, there was either spontaneous resolution of the dermatitis (n ¼ 3), or a fluctuating dermatitis occurred intermittently while on imatinib mesylate (n ¼ 2). Of the remaining six patients, five required therapy to be discontinued, but one patient managed to continue the same dose of imatinib therapy with adjunctive treatment (patient no. 10). Five evaluable patients improved within 48 h of stopping therapy (range 2-21 days). All managed to initially resume treatment with either the same (n ¼ 4), or a reduced dose (n ¼ 1) of imatinib mesylate; however, all patients developed recurrent cutaneous symptoms, the extent of which appeared to be dose related. Four patients restarted a 100 mg daily dose of imatinib mesylate, gradually incrementing to the target dose adjusted according to clinical symptoms. Owing to haematological necessity, the remaining patient (no. 9) was maintained on the same dose throughout with adjunctive prednisolone and cyclosporine. After a further 2 months, imatinib mesylate was withdrawn because of the desquamating nature of the rash and additional constitutional malaise, despite the initial achievement of both a haematological and clinical response. Imatinib mesylate therapy was not tolerated at the required dose, and the patient underwent disease progression.
Five patients required therapeutic intervention with corticosteroids (oral prednisolone, range 20-40 mg daily, or a potent topical preparation (0.05% clobetasol, patient no. 10)). Corticosteroids were initiated at the onset of the rash with a reducing regimen adjusted according to clinical symptoms, with an aim to gradually stop therapy; however, maintenance prednisone was required in patient no. 11 at 10 mg daily. Additional cyclosporine (range 100-200 mg daily) was used either alone (n ¼ 1), or in combination with corticosteroid therapy (n ¼ 4). Patient age, sex, disease stage and starting dose of imatinib mesylate did not significantly predict for skin toxicity.
In most cases, therapy with imatinib mesylate is well tolerated. Myelosuppression is well documented and the most frequent nonhaematological side effects have been gastrointestinal (nausea, diarrhoea, dyspepsia and vomiting), musculoskeletal (myalgia and arthralgia) and that of fluid retention (oedema and weight gain).
Rashes are not infrequent in patients with CML treated with imatinib mesylate. The course of the skin reaction can be self-limiting, but on occasion withdrawal of drug therapy is required. Rechallenge with imatinib mesylate can be successful and there is potential for tolerance. The rash induced appears to be mediated by a hypersensitivity reaction and may be secondary to an idiosyncratic immunological effect; however, the severity of cutaneous reactions may be dose dependent.
PDGF is known to stimulate the proliferation of a number of dermal cells including fibroblasts, as well as being chemotactic for neutrophils and macrophages 6 and the capacity of PDGF to induce a wound-healing response is well known. Most dermal cells express a receptor for PDGF, but it has not been determined whether imatinib mesylate causes a dermatitis by virtue of its tyrosine kinase inhibition. The PDGF receptor also regulates transcapillary transport, increasing dermal interstitial fluid pressure (IFP) after anaphylaxis-induced IFP reduction. 7 In addition, imatinib mesylate decreases the IFP in a rat colon carcinoma model, where PDGFb receptors are expressed in blood vessels and stromal cells, but not in tumour cells, indicating a role for PDGF receptors in tumour pathogenesis. Fluid retention has been described with PDGF receptor inhibition, and recently, fatal cerebral oedema has been documented with imatinib mesylate therapy, unrelated to leukaemia in the central nervous system. 8 Our experience demonstrates that skin-related side effects secondary to imatinib mesylate are not unsubstantial in patients with CML, can be of unique appearance and may limit therapy. Furthermore, imatinib mesylate can induce significant cutaneous morbidity, which can be potentially life threatening. Imatinib mesylate induces striking haematological and cytogenetic responses in CML patients and has a major impact on those patients who are refractory or intolerant to established treatment. We describe a profound dermatitis that appears to be unique to this particular 
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